| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.59(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.29 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
775,593 |
1,203,168 |
1,357,304 |
2,009,275 |
| Total Sell Value |
$6,587,745 |
$9,406,570 |
$9,994,774 |
$10,729,161 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
18 |
36 |
60 |
105 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ringold Gordon |
Director |
– • – |
2016-03-21 |
4 |
B |
$7.77 |
$116,540 |
I/I |
15,000 |
15,000 |
2.1 |
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2016-03-03 |
4 |
AS |
$10.74 |
$12,110 |
D/D |
(1,128) |
22,144 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2016-02-16 |
4 |
AS |
$10.25 |
$51,272 |
D/D |
(5,000) |
1,282 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2016-02-16 |
4 |
OE |
$0.54 |
$2,700 |
D/D |
5,000 |
6,282 |
|
- |
|
| Sakoda Jon |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$10,000,000 |
I/I |
1,000,000 |
1,901,869 |
1.5 |
- |
|
| Makower Joshua |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$10,000,000 |
I/I |
1,000,000 |
1,901,869 |
1.5 |
- |
|
| Kolluri Krishna Kittu |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$15,000,000 |
I/I |
1,500,000 |
1,901,869 |
1.5 |
- |
|
| Mott David M |
Director |
– • • |
2016-01-13 |
4 |
B |
$10.00 |
$10,000,000 |
I/I |
1,000,000 |
1,901,869 |
2.25 |
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$15,000,000 |
I/I |
1,500,000 |
1,901,869 |
1.5 |
- |
|
| Weller Harry R |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$10,000,000 |
I/I |
1,000,000 |
1,901,869 |
1.5 |
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$10,000,000 |
I/I |
1,000,000 |
1,901,869 |
1.5 |
- |
|
| Viswanathan Ravi |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$10,000,000 |
I/I |
1,000,000 |
1,901,869 |
1.5 |
- |
|
| Barrett M James |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$5,000,000 |
I/I |
500,000 |
7,988,893 |
1.5 |
- |
|
| Baskett Forest |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$15,000,000 |
I/I |
1,500,000 |
1,901,869 |
1.5 |
- |
|
| Nea 12 Gp, Llc |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$5,000,000 |
D/D |
500,000 |
7,988,893 |
2.45 |
- |
|
| Barris Peter J |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$15,000,000 |
I/I |
1,500,000 |
1,901,869 |
1.5 |
- |
|
| Nea 15 Gp, Llc |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$10,000,000 |
I/I |
1,000,000 |
1,901,869 |
1.5 |
- |
|
| Kerins Patrick J |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$5,000,000 |
I/I |
500,000 |
7,988,893 |
1.5 |
- |
|
| Florence Anthony A. Jr. |
10% Owner |
– – • |
2016-01-13 |
4 |
B |
$10.00 |
$10,000,000 |
I/I |
1,000,000 |
1,901,869 |
1.5 |
- |
|
| Korner Paul |
EVP, Chief Medical Officer |
• – – |
2016-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
60,753 |
60,753 |
|
- |
|
| Bertrand William C Jr |
Director |
– • – |
2015-12-17 |
4 |
B |
$20.00 |
$100,000 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| Cmea Ventures Vii (parallel) Lp |
10% Owner |
– – • |
2015-12-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(7,500) |
63,490 |
|
- |
|
| Cmea Ventures Vii (parallel) Lp |
10% Owner |
– – • |
2015-12-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(292,500) |
2,476,216 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2015-12-15 |
4 |
AS |
$20.00 |
$40,000 |
D/D |
(2,000) |
47,420 |
|
- |
|
| Jacobs Jeffrey W |
SVP, Technical Operations |
• – – |
2015-12-15 |
4 |
OE |
$0.54 |
$1,080 |
D/D |
2,000 |
49,420 |
|
- |
|
538 Records found
|
|
Page 17 of 22 |
|
|
0.08 (1.18%) 
